Medical device company Vitrolife AB (STO:VITR) on Friday reported net income of SEK71m, or EPS of SEK3.28, for the second quarter of 2017, from April 2017 to June 2017.
This was in comparison with net income of SEK48m, or EPS of SEK2.21, in Q2 of 2016.
Sales for the quarter amounted to SEK285m, up by 37% as compared with SEK208m in Q2 2016. Net sales growth was 33% in local currency.
Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.
(EUR1.00=SEK9.54)
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development